Magenta Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MGTA research report →
Price Chart
About the company
Magenta Therapeutics, Inc. is a biotechnology firm in the clinical development stage, dedicated to advancing therapies that leverage the transformative potential of stem cell transplantation for individuals afflicted with blood cancers, genetic illnesses, and autoimmune conditions. Among its key pipeline candidates is MGTA-117, an anti-CD117 antibody.
- CEO
- Stephen F. Mahoney MBA
- IPO
- 2018
- Employees
- 67
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on MGTA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $42.44M
- P/E
- -0.03
- PEG
- 0.00
- P/S
- 62.41
- P/B
- 0.00
- EV/EBITDA
- 0.68
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- -32035.88%
- Net Margin
- -28271.47%
- ROE
- -22.53%
- ROIC
- -18.47%
Latest fiscal year · YoY change
- Revenue
- $2.04M-67.3%
- Gross Profit
- $0+0.0%
- Op Income
- $-177,933,000
- Net Income
- $-162,337,000-91.1%
- EPS
- $0.00+100.0%
- OCF Growth
- -65.1%
- FCF Growth
- -65.1%
- 52W High
- $1.81
- 52W Low
- $0.32
- 50D MA
- $0.78
- 200D MA
- $0.73
- Beta
- 2.11
- RSI (14)
- 37
- Avg Volume
- 247.98K
No earnings-call transcripts are available for MGTA yet.
- Free Float
- 55.4%
- Shares Outstanding
- 60.66M
- Float Shares
- 33.64M
of shares held by institutions
54 13F filers
Buy/sell ratio 1.86. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Hellman Jordan Management Co Inc | 441.13K | ▲ 259.16K |
| Parametric Portfolio Associates LLC | 21.15K | ▲ 21.15K |
| B. Riley Wealth Management, Inc. | 10.70K | ▲ 10.70K |
| Amalgamated Financial Corp. | 4.74K | ▲ 4.74K |
| Brewin Dolphin Wealth Management Ltd | 1.30K | 0 |
Held by 13 ETFs
Biggest fund positions in MGTA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 29, 23 | Fairmount Funds Management LLC | buy | 24,670 |
| Sep 26, 23 | Fairmount Funds Management LLC | buy | 30,000 |
| Sep 22, 23 | Randhawa Simrat | buy | 2,000 |
| Sep 21, 23 | Randhawa Simrat | buy | 2,000 |
| Sep 19, 23 | Fairmount Funds Management LLC | buy | 30,000 |
| Sep 11, 23 | Meng Lei | other | 6,500 |
| Sep 11, 23 | Meng Lei | other | 0 |
| Sep 11, 23 | Violin Jonathan | other | 6,500 |
| Sep 13, 23 | Fairmount Funds Management LLC | buy | 9,367 |
| Sep 12, 23 | Fairmount Funds Management LLC | buy | 14,887 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MGTA coverage
Recent articles, reports, and earnings notes.
No research on MGTA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MGTA report →Magenta Therapeutics Announces Completion of Merger with Dianthus Therapeutics and Implementation of Reverse Stock Split
globenewswire.com · Sep 11
MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA
businesswire.com · Aug 7
10 Best-Performing Penny Stocks in the Health Care Sector
247wallst.com · Apr 3
Easing Banking Fears, Rate Hike Pause Boost Markets: 5 Picks
zacks.com · Mar 30
MGTA Stock: 51.66% Surge Explained
pulse2.com · Feb 5
Magenta (MGTA) Down on Pipeline Update for Leukemia Drug
zacks.com · Dec 21
Why The Magenta Therapeutics (MGTA) Stock Plummeted Over 50%
pulse2.com · Dec 20
Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial
globenewswire.com · Dec 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.